Testosterone Tied to Incidence, Progression of Metabolic Syndrome
2024-07-11
临床结果
THURSDAY, July 11, 2024 -- Testosterone is associated with a greater risk for development and progression of metabolic syndrome, particularly in transmasculine individuals, according to a study published online July 2 in JAMA Network Open.
Leila Hashemi, M.D., from the David Geffen School of Medicine in Los Angeles, and colleagues assessed whether gender-affirming hormone treatment (GAHT) by proxy steroid is associated with development and progression of metabolic syndrome. The analysis included 645 transgender participants and 645 matched cisgender participants.
The researchers found that metabolic syndrome z-scores changed significantly over time and differed significantly across groups. Transmasculine participants had the greatest percentage increase in mean z-scores after versus before the index GAHT date (298.0 percent), followed by cisgender females (108.3 percent), cisgender males (49.3 percent), and transfeminine persons (3.0 percent).
"In both cisgender and transgender individuals, estradiol was associated with reduced metabolic syndrome risk, whereas testosterone was associated with increased risk. These findings are relevant for the management of metabolic syndrome risk factors in cisgender and transgender individuals," the authors write. "It is also important to note that exogenous sex hormones are not equivalent to endogenous sex hormones, nor is the body in which they operate the same as one never exposed to the opposing sex hormones."
Abstract/Full Text
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
适应症
靶点
-来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。